Literature DB >> 21180545

The treatment of irritable bowel syndrome.

Brian E Lacy1, Kirsten Weiser, Ryan De Lee.   

Abstract

Irritable bowel syndrome (IBS) is a highly prevalent functional bowel disorder routinely encountered by healthcare providers. Although not life-threatening, this chronic disorder reduces patients' quality of life and imposes a significant economic burden to the healthcare system. IBS is no longer considered a diagnosis of exclusion that can only be made after performing a battery of expensive diagnostic tests. Rather, IBS should be confidently diagnosed in the clinic at the time of the first visit using the Rome III criteria and a careful history and physical examination. Treatment options for IBS have increased in number in the past decade and clinicians should not be limited to using only fiber supplements and smooth muscle relaxants. Although all patients with IBS have symptoms of abdominal pain and disordered defecation, treatment needs to be individualized and should focus on the predominant symptom. This paper will review therapeutic options for the treatment of IBS using a tailored approach based on the predominant symptom. Abdominal pain, bloating, constipation and diarrhea are the four main symptoms that can be addressed using a combination of dietary interventions and medications. Treatment options include probiotics, antibiotics, tricyclic antidepressants, selective serotonin reuptake inhibitors and agents that modulate chloride channels and serotonin. Each class of agent will be reviewed using the latest data from the literature.

Entities:  

Keywords:  abdominal pain; alosetron; bloating; constipation; diarrhea; irritable bowel syndrome; lubiprostone; probiotics; tegaserod; tricyclic antidepressants

Year:  2009        PMID: 21180545      PMCID: PMC3002524          DOI: 10.1177/1756283X09104794

Source DB:  PubMed          Journal:  Therap Adv Gastroenterol        ISSN: 1756-283X            Impact factor:   4.409


  106 in total

1.  Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome.

Authors:  T Poynard; C Regimbeau; Y Benhamou
Journal:  Aliment Pharmacol Ther       Date:  2001-03       Impact factor: 8.171

2.  Non-absorbable antibiotics for managing intestinal gas production and gas-related symptoms.

Authors:  M Di Stefano; A Strocchi; S Malservisi; G Veneto; A Ferrieri; G R Corazza
Journal:  Aliment Pharmacol Ther       Date:  2000-08       Impact factor: 8.171

3.  Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome.

Authors:  M Pimentel; E J Chow; H C Lin
Journal:  Am J Gastroenterol       Date:  2000-12       Impact factor: 10.864

Review 4.  Anticonvulsant drugs for acute and chronic pain.

Authors:  P Wiffen; S Collins; H McQuay; D Carroll; A Jadad; A Moore
Journal:  Cochrane Database Syst Rev       Date:  2000

5.  Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis.

Authors:  J L Jackson; P G O'Malley; G Tomkins; E Balden; J Santoro; K Kroenke
Journal:  Am J Med       Date:  2000-01       Impact factor: 4.965

6.  The impact of irritable bowel syndrome on health-related quality of life.

Authors:  I M Gralnek; R D Hays; A Kilbourne; B Naliboff; E A Mayer
Journal:  Gastroenterology       Date:  2000-09       Impact factor: 22.682

Review 7.  Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials.

Authors:  J Jailwala; T F Imperiale; K Kroenke
Journal:  Ann Intern Med       Date:  2000-07-18       Impact factor: 25.391

8.  Impaired transit and tolerance of intestinal gas in the irritable bowel syndrome.

Authors:  J Serra; F Azpiroz; J R Malagelada
Journal:  Gut       Date:  2001-01       Impact factor: 23.059

9.  Alosetron, a 5-HT3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers.

Authors:  L A Houghton; J M Foster; P J Whorwell
Journal:  Aliment Pharmacol Ther       Date:  2000-06       Impact factor: 8.171

10.  Health-related quality of life and health care costs in severe, refractory irritable bowel syndrome.

Authors:  F Creed; J Ratcliffe; L Fernandez; B Tomenson; S Palmer; C Rigby; E Guthrie; N Read; D Thompson
Journal:  Ann Intern Med       Date:  2001-05-01       Impact factor: 25.391

View more
  19 in total

1.  Linaclotide: a novel therapy for chronic constipation and constipation-predominant irritable bowel syndrome.

Authors:  Brian E Lacy; John M Levenick; Michael D Crowell
Journal:  Gastroenterol Hepatol (N Y)       Date:  2012-10

2.  NaV1.1 inhibition can reduce visceral hypersensitivity.

Authors:  Juan Salvatierra; Joel Castro; Andelain Erickson; Qian Li; Joao Braz; John Gilchrist; Luke Grundy; Grigori Y Rychkov; Annemie Deiteren; Rana Rais; Glenn F King; Barbara S Slusher; Allan Basbaum; Pankaj J Pasricha; Stuart M Brierley; Frank Bosmans
Journal:  JCI Insight       Date:  2018-06-07

Review 3.  Recent advances in pharmacological treatment of irritable bowel syndrome.

Authors:  Georgia Lazaraki; Grigoris Chatzimavroudis; Panagiotis Katsinelos
Journal:  World J Gastroenterol       Date:  2014-07-21       Impact factor: 5.742

Review 4.  Irritable bowel syndrome diagnosis and management: A simplified algorithm for clinical practice.

Authors:  Paul Moayyedi; Fermín Mearin; Fernando Azpiroz; Viola Andresen; Giovanni Barbara; Maura Corsetti; Anton Emmanuel; A Pali S Hungin; Peter Layer; Vincenzo Stanghellini; Peter Whorwell; Frank Zerbib; Jan Tack
Journal:  United European Gastroenterol J       Date:  2017-09-28       Impact factor: 4.623

5.  Targeted therapies for diarrhea-predominant irritable bowel syndrome.

Authors:  Kevin W Olden
Journal:  Clin Exp Gastroenterol       Date:  2012-05-25

6.  The impact of abdominal pain on global measures in patients with chronic idiopathic constipation, before and after treatment with linaclotide: a pooled analysis of two randomised, double-blind, placebo-controlled, phase 3 trials.

Authors:  L Chang; A J Lembo; B J Lavins; S J Shiff; X Hao; J G Chickering; X D Jia; M G Currie; C B Kurtz; J M Johnston
Journal:  Aliment Pharmacol Ther       Date:  2014-10-13       Impact factor: 8.171

Review 7.  Clinical Practice Guidelines for Irritable Bowel Syndrome in Korea, 2017 Revised Edition.

Authors:  Kyung Ho Song; Hye-Kyung Jung; Hyun Jin Kim; Hoon Sup Koo; Yong Hwan Kwon; Hyun Duk Shin; Hyun Chul Lim; Jeong Eun Shin; Sung Eun Kim; Dae Hyeon Cho; Jeong Hwan Kim; Hyun Jung Kim
Journal:  J Neurogastroenterol Motil       Date:  2018-04-30       Impact factor: 4.924

8.  Development and validation of the Health Promoting Behaviour for Bloating (HPB-Bloat) scale.

Authors:  Nurzulaikha Abdullah; Yee Cheng Kueh; Garry Kuan; Mung Seong Wong; Fatan Hamamah Yahaya; Nor Aslina Abd Samat; Khairil Khuzaini Zulkifli; Yeong Yeh Lee
Journal:  PeerJ       Date:  2021-06-04       Impact factor: 2.984

9.  The gut microbiota and irritable bowel syndrome: friend or foe?

Authors:  Uday C Ghoshal; Ratnakar Shukla; Ujjala Ghoshal; Kok-Ann Gwee; Siew C Ng; Eamonn M M Quigley
Journal:  Int J Inflam       Date:  2012-04-22

Review 10.  The role of primary care physicians in early diagnosis and treatment of chronic gastrointestinal diseases.

Authors:  Aristofanis Gikas; John K Triantafillidis
Journal:  Int J Gen Med       Date:  2014-03-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.